Top Markets
Coin of the day
Golden Biotechnology Corporation Golden Biotechnology Corporation

Golden Biotechnology Corporation

4132
Rankning i aktier #29677
Golden Biotechnology Corporation, founded in 2002 and based in New Taipei City,... Golden Biotechnology Corporation, founded in 2002 and based in New Taipei City, Taiwan, is engaged in both pharmaceutical drug discovery and the production of health-enhancing dietary supplements. The company operates internationally, serving markets in Taiwan, the United States, Japan, China, Korea, and Singapore. Its varied product line includes several health supplements: Liverty, formulated to support liver function and help alleviate fatigue. Rasle, which serves as an adjunctive therapy for autoimmune conditions. ZSAINO, a nutritional product designed to aid recovery from illness and boost general well-being. UMOOZE, a specialized herbal blend targeting optimal health for men. Furthermore, Golden Biotechnology is developing Antroquinonol, an anticancer molecule. This compound is currently utilized in the treatment of severe conditions such as pancreatic cancer, acute myeloid leukemia, and hepatocellular carcinoma, in addition to addressing hypercholesterolemia and hyperlipidemia.
Aktiekurs
$0.11034263
Senast synkroniserad: 2026-04-09
Marknadsvärde
$20.11M
Förändring (1 dag)
-31.83%
Förändring (1 år)
-73.09%
Land
TW
Handel Golden Biotechnology Corporation (4132)

Kategori

Utdelningshistorik för Golden Biotechnology Corporation (4132)
Golden Biotechnology Corporation (aktiens symbol: 4132) har gjort totalt 0 utdelningsbetalningar.
Summan av alla utdelningar (justerat för aktiesplitar) är: 0.00
Utdelningsavkastning (TTM): 0
Utdelningsbetalningar för Golden Biotechnology Corporation (4132) från 2026 till 2026
Årliga utdelningsbetalningar
År Utdelning (justerat för aktiesplitar) Ändra
Inte tillräckligt med data för de angivna datumen.
Lista över alla utdelningsbetalningar
År Utdelning Ändra
Inte tillräckligt med data för de angivna datumen.
Utdelningar för liknande företag eller konkurrenter